Kisqali Interactions
There are 708 drugs known to interact with Kisqali (ribociclib), along with 6 disease interactions, and 1 alcohol/food interaction. Of the total drug interactions, 302 are major, 394 are moderate, and 12 are minor.
- View all 708 medications that may interact with Kisqali
- View Kisqali alcohol/food interactions (1)
- View Kisqali disease interactions (6)
Most frequently checked interactions
View interaction reports for Kisqali (ribociclib) and the medicines listed below.
- Afinitor (everolimus)
- amlodipine
- atorvastatin
- calcium carbonate
- calcium / vitamin d
- Claritin (loratadine)
- Faslodex (fulvestrant)
- Femara (letrozole)
- fulvestrant
- gabapentin
- Ibrance (palbociclib)
- letrozole
- levothyroxine
- lisinopril
- losartan
- Lupron (leuprolide)
- metformin
- metoprolol
- Metoprolol Succinate ER (metoprolol)
- omeprazole
- ondansetron
- oxycodone
- pantoprazole
- Prilosec (omeprazole)
- tramadol
- turmeric
- Vitamin D3 (cholecalciferol)
- Xgeva (denosumab)
- Zometa (zoledronic acid)
- Zyrtec (cetirizine)
Kisqali alcohol/food interactions
There is 1 alcohol/food interaction with Kisqali (ribociclib).
Kisqali disease interactions
There are 6 disease interactions with Kisqali (ribociclib) which include:
- Ribociclib – arrhythmias
- lung toxicity
- cutaneous toxicity
- hepatic impairment
- neutropenia
- renal impairment
More about Kisqali (ribociclib)
- Kisqali consumer information
- Compare alternatives
- Reviews (24)
- Imprints, shape & color data
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CDK 4/6 inhibitors
- Breastfeeding
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.